BACKGROUND: Tobacco exposure is routinely assessed by quantifying nicotine metabolites in plasma or urine. On average, 80% of nicotine undergoes C-oxidation to cotinine. However, interindividual variation in nicotine glucuronidation is substantial, and glucuronidation accounts for from 0% to 40% of total nicotine metabolism. We report here the effect of a polymorphism in a UDP-glucuronsyltransferase, UGT2B10, on nicotine metabolism and consumption. METHODS: Nicotine, cotinine, their N-glucuronide conjugates, and total trans-3'-hydroxycotinine were quantified in the urine (n = 327) and plasma (n = 115) of smokers. Urinary nicotine N-oxide was quantified in 105 smokers. Nicotine equivalents, the sum of nicotine and all major metabolites, were calculated for each smoker. The relationship of the UGT2B10 Asp67Tyr allele to nicotine equivalents, N-glucuronidation, and C-oxidation was determined. RESULTS: Individuals heterozygous for the Asp67Tyr allele excreted less nicotine or cotinine as their glucuronide conjugates than did wild-type, resulting in a 60% lower ratio of cotinine glucuronide to cotinine, a 50% lower ratio of nicotine glucuronide to nicotine, and increased cotinine and trans-3'-hydroxycotinine. Nicotine equivalents, a robust biomarker of nicotine intake, were lower among Asp67Tyr heterozygotes compared with individuals without this allele: 58.2 (95% confidence interval, 48.9-68.2) versus 69.2 nmol/mL (95% confidence interval, 64.3-74.5). CONCLUSIONS: Individuals heterozygous for UGT2B10 Asp67Tyr consume less nicotine than do wild-type smokers. This striking observation suggests that variations in nicotine N-glucuronidation, as reported for nicotine C-oxidation, may influence smoking behavior. IMPACT: UGT2B10 genotype influences nicotine metabolism and should be taken into account when characterizing the role of nicotine metabolism on smoking. Copyright 2010 AACR.
BACKGROUND:Tobacco exposure is routinely assessed by quantifying nicotine metabolites in plasma or urine. On average, 80% of nicotine undergoes C-oxidation to cotinine. However, interindividual variation in nicotine glucuronidation is substantial, and glucuronidation accounts for from 0% to 40% of total nicotine metabolism. We report here the effect of a polymorphism in a UDP-glucuronsyltransferase, UGT2B10, on nicotine metabolism and consumption. METHODS:Nicotine, cotinine, their N-glucuronide conjugates, and total trans-3'-hydroxycotinine were quantified in the urine (n = 327) and plasma (n = 115) of smokers. Urinary nicotine N-oxide was quantified in 105 smokers. Nicotine equivalents, the sum of nicotine and all major metabolites, were calculated for each smoker. The relationship of the UGT2B10Asp67Tyr allele to nicotine equivalents, N-glucuronidation, and C-oxidation was determined. RESULTS: Individuals heterozygous for the Asp67Tyr allele excreted less nicotine or cotinine as their glucuronide conjugates than did wild-type, resulting in a 60% lower ratio of cotinine glucuronide to cotinine, a 50% lower ratio of nicotine glucuronide to nicotine, and increased cotinine and trans-3'-hydroxycotinine. Nicotine equivalents, a robust biomarker of nicotine intake, were lower among Asp67Tyr heterozygotes compared with individuals without this allele: 58.2 (95% confidence interval, 48.9-68.2) versus 69.2 nmol/mL (95% confidence interval, 64.3-74.5). CONCLUSIONS: Individuals heterozygous for UGT2B10Asp67Tyr consume less nicotine than do wild-type smokers. This striking observation suggests that variations in nicotine N-glucuronidation, as reported for nicotine C-oxidation, may influence smoking behavior. IMPACT: UGT2B10 genotype influences nicotine metabolism and should be taken into account when characterizing the role of nicotine metabolism on smoking. Copyright 2010 AACR.
Authors: Sharon E Murphy; Carrie A Link; Joni Jensen; Chap Le; Susan S Puumala; Stephen S Hecht; Steven G Carmella; London Losey; Dorothy K Hatsukami Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-10 Impact factor: 4.254
Authors: Ursula Ehmer; Arndt Vogel; Jan Karl Schütte; Britta Krone; Michael P Manns; Christian P Strassburg Journal: Hepatology Date: 2004-04 Impact factor: 17.425
Authors: Sharon E Murphy; Christopher J Sipe; Kwangsoo Choi; Leah M Raddatz; Joseph S Koopmeiners; Eric C Donny; Dorothy K Hatsukami Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-03-06 Impact factor: 4.254
Authors: Rachel I Vogel; Steven G Carmella; Irina Stepanov; Dorothy K Hatsukami; Stephen S Hecht Journal: Biomarkers Date: 2011-08-03 Impact factor: 2.658
Authors: Catherine A Wassenaar; David V Conti; Soma Das; Peixian Chen; Edwin H Cook; Mark J Ratain; Neal L Benowitz; Rachel F Tyndale Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-02 Impact factor: 4.254
Authors: Sharon E Murphy; Linda B von Weymarn; Marc Parenteau; Irina Stepanov; Maarit Tiirikainen; Loic LeMarchand; Sungshim L Park Journal: Chem Res Toxicol Date: 2018-02-28 Impact factor: 3.739
Authors: Sharon E Murphy; Sung-Shim L Park; Elizabeth F Thompson; Lynne R Wilkens; Yesha Patel; Daniel O Stram; Loic Le Marchand Journal: Carcinogenesis Date: 2014-09-18 Impact factor: 4.944
Authors: Yesha M Patel; Daniel O Stram; Lynne R Wilkens; Sung-Shim L Park; Brian E Henderson; Loic Le Marchand; Christopher A Haiman; Sharon E Murphy Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-07 Impact factor: 4.254
Authors: A Joseph Bloom; Linda B von Weymarn; Maribel Martinez; Laura J Bierut; Alison Goate; Sharon E Murphy Journal: Pharmacogenet Genomics Date: 2013-12 Impact factor: 2.089